MDS (Myelodysplastic Syndrome)NCT07561385
Dresden MDS Registry With an Accompanying Biomaterial Collection
An observational study of MDS (Myelodysplastic Syndrome) and MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome, run by Technische Universität Dresden at 1 site in Germany.
Trial summary
A registry for the study of the epidemiology, clinical course, and progression of myelodysplastic neoplasms (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN overlap syndromes), and their precursor syndromes (CHIP, CCUS) Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- MDS (Myelodysplastic Syndrome), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome, CHIP
- How many people
- 500 participants
- Where
- 1 siteGermany
- Study dates
- Sep 2026to Jun 2036
- How long will I take part?
- 5 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Diagnosis of myelodysplastic syndrome (MDS), MDS/MPN overlap syndrome, or evidence of a myelodysplastic precursor syndrome, defined as clonal hematopoiesis without cytopenia (clonal hematopoiesis of indeterminate potential, CHIP) or clonal hematopoiesis with cytopenia (clonal cytopenia of undetermined significance, CCUS) according to current WHO criteria
Who may be able to join
- Diagnosis of myelodysplastic syndrome (MDS), MDS/MPN overlap syndrome or evidence of myelodysplastic precursor syndrome, defined as clonal haematopoiesis without cytopenia (clonal haematopoiesis of indeterminate potential, CHIP) or clonal haematopoiesis with cytopenia (clonal cytopenia of undetermined significance, CCUS) in accordance with current WHO criteria
- Age ≥18 years
- Submission of a signed consent form for participation in the MDS Registry
Who cannot join
- No exclusion criteria have been established with regard to the registry's primary objective. In particular, patients with comorbidities and those receiving non-curative treatment may be explicitly included in order to provide a realistic picture of actual care practices
- Inclusion in the registry is excluded in cases where a written consent form is not available or where patients are unable to understand the nature and implications of participating in this registry
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Ekaterina Balaian, Dr. med. contact
Germany1 site
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, 01307
Katja Sockel, Dr. med., +493514580, Katja.Sockel@ukdd.de
Ekaterina Balaian, Dr. med.
About this study
A registry for the study of the epidemiology, clinical course, and progression of myelodysplastic neoplasms (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN overlap syndromes), and their precursor syndromes (CHIP, CCUS)
- Conditions
- MDS (Myelodysplastic Syndrome), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome, CHIP, CCUS Clonal Cytopenia of Undetermined Significance
- Medical subject headings
- Anemia, Refractory, with Excess of Blasts
What is being measured
The primary outcome is the main question the study is designed to answer.
Collection of epidemiological data on MDS, MDS/MPN overlap syndromes and their precursor syndromes (CHIP, CCUS)
Measured: 10 Years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2026
- Study startSep 2026 (estimated)
- Primary completionJun 2036 (estimated)
- Study completionJun 2036 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MDS (Myelodysplastic Syndrome)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Technische Universität Dresden
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07561385
- Sponsor's protocol ID
- Dresdner MDS-Register
- Status last verified
- Aug 2026
- First submitted
- 20 Apr 2026
- Last updated
- 27 Aug 2026
- Results posted
- No